FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001088099> ?p ?o ?g. }

• W2001088099 abstract "Background. Activation of the PI3K pathway is associated with resistance to endocrine treatments (ET) in luminal breast cancer (LBC). Everolimus, an mTOR inhibitor, has been approved in combination with exemestane in endocrine resistant breast tumors. However, no definite signature of ET resistance or predictive factors of sensitivity to everolimus (EVE) treatment have been evidenced so far. In order to further decipher these molecular patterns, we used patient derived LBC xenografts (LBC-PDX) treated with various ET and EVE based combinations. Methods. 3 LBC-PDX (named HBCx-3, HBCx-21 and HBCx-34) were treated with ET during several months to establish hormono-resistant (HR) xenografts. Both parental and HR models were treated by tamoxifen, estrogen deprivation, fulvestrant, EVE alone, and EVE combined with all three ET modalities. Tissue Micro Arrays from control and treated tumor samples were generated for IHC analyses. RT-PCR analyses were conducted on genes related to proliferation, ER, PI3K, IGF-1R and angiogenesis pathways. Results. In primary PDX, ET showed a poor level of sensitivity for HBCx-3 and a high and sustained efficacy of ER targeting and/or ER deprivation for HBCx-21 and HBCx-34 tumors. In vivo resistance to ET was confirmed in all HR variants with tumor growth rates faster than parental xenografts. ER expression was conserved in HR tumors, but expression of the ER-responsive genes PS2, PR and MYB was strongly decreased, indicating impaired ER transcriptional activity. Acquired resistance to tamoxifen and ovariectomy was also associated to a strong decrease of IGF-1R signaling in HBCx-21, and was related to higher P-AKT expression, although P-pS6 was highly expressed in both sensitive and resistant tumors. Furthermore, in vivo experiments showed that EVE alone was highly efficient in all models independently of P-AKT expression/PTEN loss. EVE combined with fulvestrant yielded the most complete and durable tumor growth inhibition. In HBCx-3, proliferation and pS6 levels were markedly decreased only by the EVE-fulvestrant combination. In HBCx-21 and HBCx-34 HR models, EVE-based treatments decreased proliferation, expression of angiogenesis markers, as well as P-pS6 expression with no variation in (P-)AKT nor (P-)mTOR levels. A high IGF-1R protein expression was found only in the HBCx-34 TAM-R tumor, which was strongly decreased in the fulvestrant-treated tumors. Conclusions. LBC-PDX with confirmed HR status have been established and may serve as models to study alternate therapies. Of note, in the HBCx-21 and -34 models, activation of the PI3K pathway is poorly correlated with baseline sensitivity to ET, suggesting other pathways of resistance. EVE alone is highly efficient in all settings, and combination with fulvestrant is promising at the in vivo and molecular levels. Proteomic, genomic and gene expression studies are ongoing. Citation Format: Paul H. Cottu, Thomas Bagarre, Jean-Jacques Fontaine, Franck Assayag, Sophie Richon, Sophie Chateau-Joubert, Aurelie Thuleau, Patricia de Cremoux, Khemaies Slimane, Didier Decaudin, Anne Vincent-Salomon, Ivan Bieche, Elisabetta Marangoni. Endocrine resistant luminal breast cancer xenografts are powerful models for the analysis of sensitivity to endocrine and everolimus treatments . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 85. doi:10.1158/1538-7445.AM2013-85" @default.
• W2001088099 created "2016-06-24" @default.
• W2001088099 creator A5012603842 @default.
• W2001088099 creator A5021300076 @default.
• W2001088099 creator A5034058277 @default.
• W2001088099 creator A5035469867 @default.
• W2001088099 creator A5037340510 @default.
• W2001088099 creator A5037964830 @default.
• W2001088099 creator A5039706842 @default.
• W2001088099 creator A5042551220 @default.
• W2001088099 creator A5051159630 @default.
• W2001088099 creator A5059398124 @default.
• W2001088099 creator A5068603135 @default.
• W2001088099 creator A5087405971 @default.
• W2001088099 creator A5089229030 @default.
• W2001088099 date "2013-04-15" @default.
• W2001088099 modified "2023-10-14" @default.
• W2001088099 title "Abstract 85: Endocrine resistant luminal breast cancer xenografts are powerful models for the analysis of sensitivity to endocrine and everolimus treatments ." @default.
• W2001088099 doi "https://doi.org/10.1158/1538-7445.am2013-85" @default.
• W2001088099 hasPublicationYear "2013" @default.
• W2001088099 type Work @default.
• W2001088099 sameAs 2001088099 @default.
• W2001088099 citedByCount "0" @default.
• W2001088099 crossrefType "proceedings-article" @default.
• W2001088099 hasAuthorship W2001088099A5012603842 @default.
• W2001088099 hasAuthorship W2001088099A5021300076 @default.
• W2001088099 hasAuthorship W2001088099A5034058277 @default.
• W2001088099 hasAuthorship W2001088099A5035469867 @default.
• W2001088099 hasAuthorship W2001088099A5037340510 @default.
• W2001088099 hasAuthorship W2001088099A5037964830 @default.
• W2001088099 hasAuthorship W2001088099A5039706842 @default.
• W2001088099 hasAuthorship W2001088099A5042551220 @default.
• W2001088099 hasAuthorship W2001088099A5051159630 @default.
• W2001088099 hasAuthorship W2001088099A5059398124 @default.
• W2001088099 hasAuthorship W2001088099A5068603135 @default.
• W2001088099 hasAuthorship W2001088099A5087405971 @default.
• W2001088099 hasAuthorship W2001088099A5089229030 @default.
• W2001088099 hasConcept C121608353 @default.
• W2001088099 hasConcept C126322002 @default.
• W2001088099 hasConcept C134018914 @default.
• W2001088099 hasConcept C143998085 @default.
• W2001088099 hasConcept C2775860665 @default.
• W2001088099 hasConcept C2777176818 @default.
• W2001088099 hasConcept C2779699572 @default.
• W2001088099 hasConcept C2780482068 @default.
• W2001088099 hasConcept C46699223 @default.
• W2001088099 hasConcept C502942594 @default.
• W2001088099 hasConcept C530470458 @default.
• W2001088099 hasConcept C55493867 @default.
• W2001088099 hasConcept C62478195 @default.
• W2001088099 hasConcept C71315377 @default.
• W2001088099 hasConcept C71924100 @default.
• W2001088099 hasConcept C86554907 @default.
• W2001088099 hasConcept C86803240 @default.
• W2001088099 hasConceptScore W2001088099C121608353 @default.
• W2001088099 hasConceptScore W2001088099C126322002 @default.
• W2001088099 hasConceptScore W2001088099C134018914 @default.
• W2001088099 hasConceptScore W2001088099C143998085 @default.
• W2001088099 hasConceptScore W2001088099C2775860665 @default.
• W2001088099 hasConceptScore W2001088099C2777176818 @default.
• W2001088099 hasConceptScore W2001088099C2779699572 @default.
• W2001088099 hasConceptScore W2001088099C2780482068 @default.
• W2001088099 hasConceptScore W2001088099C46699223 @default.
• W2001088099 hasConceptScore W2001088099C502942594 @default.
• W2001088099 hasConceptScore W2001088099C530470458 @default.
• W2001088099 hasConceptScore W2001088099C55493867 @default.
• W2001088099 hasConceptScore W2001088099C62478195 @default.
• W2001088099 hasConceptScore W2001088099C71315377 @default.
• W2001088099 hasConceptScore W2001088099C71924100 @default.
• W2001088099 hasConceptScore W2001088099C86554907 @default.
• W2001088099 hasConceptScore W2001088099C86803240 @default.
• W2001088099 hasLocation W20010880991 @default.
• W2001088099 hasOpenAccess W2001088099 @default.
• W2001088099 hasPrimaryLocation W20010880991 @default.
• W2001088099 hasRelatedWork W1484562536 @default.
• W2001088099 hasRelatedWork W2036980023 @default.
• W2001088099 hasRelatedWork W2044119137 @default.
• W2001088099 hasRelatedWork W2077252057 @default.
• W2001088099 hasRelatedWork W2081793436 @default.
• W2001088099 hasRelatedWork W2088679011 @default.
• W2001088099 hasRelatedWork W2161305430 @default.
• W2001088099 hasRelatedWork W2203191607 @default.
• W2001088099 hasRelatedWork W2284004673 @default.
• W2001088099 hasRelatedWork W2317592792 @default.
• W2001088099 hasRelatedWork W2427869665 @default.
• W2001088099 hasRelatedWork W2469070792 @default.
• W2001088099 hasRelatedWork W2740838738 @default.
• W2001088099 hasRelatedWork W2741604296 @default.
• W2001088099 hasRelatedWork W2792629101 @default.
• W2001088099 hasRelatedWork W2793662481 @default.
• W2001088099 hasRelatedWork W2944568957 @default.
• W2001088099 hasRelatedWork W2956076791 @default.
• W2001088099 hasRelatedWork W3008892546 @default.
• W2001088099 hasRelatedWork W3010516724 @default.
• W2001088099 isParatext "false" @default.
• W2001088099 isRetracted "false" @default.
• W2001088099 magId "2001088099" @default.
• W2001088099 workType "article" @default.